Algahtani Thikra, Le Ruez Tom, Strang John, Morgan David, Smith Martin, Copeland Caroline S
Centre for Pharmaceutical Medicine Research, Institute of Pharmaceutical Science, King's College London, London, UK.
Freelance consultant.
Addiction. 2025 Jul;120(7):1460-1465. doi: 10.1111/add.70015. Epub 2025 Feb 13.
Long-term treatment of opioid dependence with the opioid agonist therapy (OAT) methadone can lead to significant weight gain. This study investigated whether OAT patients with a body mass index (BMI) deemed overweight (≥25) are at increased risk of mortality.
A retrospective case-control study was performed with anonymised data collected from living and deceased persons registered as receiving OAT from Derbyshire or Teesside drug and alcohol services in the United Kingdom. Height, weight, age, gender, OAT type and dose, smoking status and postcode of usual address were collected. Cause of death was collected from deceased individuals. Adjusted odds ratios (aOR) and 95% confidence intervals (95% CI) were calculated using regression models.
Data were collected for 1574 living and 233 deceased individuals. Mean BMI of all individuals (25.75 ± 6.56) was above the threshold considered a healthy weight, and was higher in deceased (26.63 ± 7.87) than living individuals (25.61 ± 6.34; P < 0.05). A BMI of 30 corresponded to an average 7.7% increased risk of mortality, increasing to 37.2% for those with a BMI of 35 and 107.3% for those with a BMI of 40. Risk of death also increased by an average of 43.6% for those deemed underweight (BMI 15). People who were older (mean aOR = 1.019; 95% CI = 1.002-1.036), smoked (mean aOR = 2.917; 95% CI = 1.726-4.934) and lived in more deprived areas (mean aOR = 0.891; 95% CI = 0.831-0.956) were more likely to have died, as were those prescribed methadone (vs buprenorphine) (mean aOR = 1.916; 95% CI = 1.138-3.227). There was no significant effect of gender (mean aOR = 0.844; 95% CI = 0.612-1.162) or methadone dose (aOR = 0.995; 95% CI = 0.988-1.001) on incidence of death. Acute drug toxicity was the predominant underlying cause of death for healthy and overweight people (46% of cases in both groups), with cancer (21% of cases) and infection (18% of cases) greater contributors to cause of death in underweight people.
Opioid agonist therapy (OAT) patients with a body mass index outside of the 'healthy' range appear to have an increased risk of death compared with OAT patients within the 'healthy' range.
使用阿片类激动剂疗法(OAT)美沙酮对阿片类药物依赖进行长期治疗可能会导致显著体重增加。本研究调查了体重指数(BMI)被视为超重(≥25)的OAT患者是否有更高的死亡风险。
进行了一项回顾性病例对照研究,使用从英国德比郡或蒂赛德药物与酒精服务机构登记接受OAT的在世者和逝者收集的匿名数据。收集身高、体重、年龄、性别、OAT类型和剂量、吸烟状况以及常住地址的邮政编码。从逝者个体收集死亡原因。使用回归模型计算调整后的比值比(aOR)和95%置信区间(95%CI)。
收集了1574名在世者和233名逝者的数据。所有个体的平均BMI(25.75±6.56)高于被视为健康体重的阈值,逝者的BMI(26.63±7.87)高于在世者(25.61±6.34;P<0.05)。BMI为30时,死亡风险平均增加7.7%,BMI为35者增加到37.2%,BMI为40者增加到107.3%。体重过轻(BMI 15)者的死亡风险平均也增加43.6%。年龄较大(平均aOR = 1.019;95%CI = 1.002 - 1.036)、吸烟(平均aOR = 2.917;95%CI = 1.726 - 4.934)以及居住在贫困程度更高地区(平均aOR = 0.891;95%CI = 0.831 - 0.956)的人更有可能死亡,接受美沙酮治疗(与丁丙诺啡相比)的人也是如此(平均aOR = 1.916;95%CI = 1.138 - 3.227)。性别(平均aOR = 0.844;95%CI = 0.612 - 1.162)或美沙酮剂量(aOR = 0.995;95%CI = 0.988 - 1.001)对死亡发生率没有显著影响。急性药物毒性是健康和超重人群死亡的主要潜在原因(两组病例均占46%),癌症(占病例的21%)和感染(占病例的18%)在体重过轻人群的死亡原因中占比更大。
与“健康”范围内的OAT患者相比,体重指数超出“健康”范围的阿片类激动剂疗法(OAT)患者似乎有更高的死亡风险。